$We_Beat_Wallstreet

[mudturtle]

LXRX 1.00 (roi) Target 1.20

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinical trial for the treatment of rheumatoid arthritis; and LX7101, a topically-delivered small molecule compound that has completed Phase 1 clinical trial for the treatment of glaucoma. Further, the company?s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has drug discovery and development collaborations with Bristol-Myers Squibb Company, Genentech, Inc., and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.